High‑Cost, High‑Benefit: A New Look at MS Drugs in Brazil

A large Brazilian health insurer recently ran a study to see how expensive but powerful medicines for multiple sclerosis (MS) stack up against one another. The goal was to find out which drugs give the best value for money when they are used by many patients. Instead of simply listing prices, the analysis paired each drug’s cost with its effectiveness in slowing disease progression. The result was a ranking that shows which treatments deliver the most benefit for each dollar spent.The findings suggest that while some of the newer, high‑efficacy medicines are pricey, they can actually save money in the long run by reducing hospital visits and disability. In contrast, cheaper options may require more frequent medical care, adding to overall costs. These insights can help policymakers and insurance companies decide how to allocate limited resources while still offering patients the most advanced care. The study also highlights the importance of measuring both health outcomes and economic impact when evaluating new therapies.